RU2008130893A - Адипогенные аденовирусы как биомаркеры заболеваний - Google Patents
Адипогенные аденовирусы как биомаркеры заболеваний Download PDFInfo
- Publication number
- RU2008130893A RU2008130893A RU2008130893/13A RU2008130893A RU2008130893A RU 2008130893 A RU2008130893 A RU 2008130893A RU 2008130893/13 A RU2008130893/13 A RU 2008130893/13A RU 2008130893 A RU2008130893 A RU 2008130893A RU 2008130893 A RU2008130893 A RU 2008130893A
- Authority
- RU
- Russia
- Prior art keywords
- adenovirus
- individual
- adipogenic
- sample
- group
- Prior art date
Links
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract 42
- 230000002293 adipogenic effect Effects 0.000 title claims abstract 30
- 201000010099 disease Diseases 0.000 title claims abstract 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract 8
- 239000000090 biomarker Substances 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 37
- 201000011510 cancer Diseases 0.000 claims abstract 7
- 206010028980 Neoplasm Diseases 0.000 claims abstract 6
- 238000012216 screening Methods 0.000 claims abstract 6
- 241000700605 Viruses Species 0.000 claims abstract 5
- 206010006187 Breast cancer Diseases 0.000 claims abstract 4
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract 4
- 206010060862 Prostate cancer Diseases 0.000 claims abstract 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract 4
- 150000007523 nucleic acids Chemical group 0.000 claims abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 4
- 238000002965 ELISA Methods 0.000 claims abstract 3
- 208000019693 Lung disease Diseases 0.000 claims abstract 3
- 208000016222 Pancreatic disease Diseases 0.000 claims abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract 3
- 230000004064 dysfunction Effects 0.000 claims abstract 3
- 210000000653 nervous system Anatomy 0.000 claims abstract 3
- 238000006386 neutralization reaction Methods 0.000 claims abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 3
- 230000000405 serological effect Effects 0.000 claims abstract 3
- 210000004100 adrenal gland Anatomy 0.000 claims abstract 2
- 230000005978 brain dysfunction Effects 0.000 claims abstract 2
- 238000006243 chemical reaction Methods 0.000 claims abstract 2
- 230000006589 gland dysfunction Effects 0.000 claims abstract 2
- 239000000523 sample Substances 0.000 claims 13
- 229960005486 vaccine Drugs 0.000 claims 3
- 239000012472 biological sample Substances 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 210000001124 body fluid Anatomy 0.000 claims 2
- 239000010839 body fluid Substances 0.000 claims 2
- 210000003608 fece Anatomy 0.000 claims 2
- -1 feces Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 210000003296 saliva Anatomy 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 claims 1
- 101710132601 Capsid protein Proteins 0.000 claims 1
- 101710094648 Coat protein Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 101710125418 Major capsid protein Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 101710141454 Nucleoprotein Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 101710083689 Probable capsid protein Proteins 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/075—Adenoviridae
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75340205P | 2005-12-27 | 2005-12-27 | |
| US60/753,402 | 2005-12-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008130893A true RU2008130893A (ru) | 2010-02-10 |
Family
ID=38610014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008130893/13A RU2008130893A (ru) | 2005-12-27 | 2006-12-27 | Адипогенные аденовирусы как биомаркеры заболеваний |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US7442511B2 (enExample) |
| EP (2) | EP2390372A1 (enExample) |
| JP (1) | JP2009521707A (enExample) |
| KR (1) | KR20080114683A (enExample) |
| CN (1) | CN101389768B (enExample) |
| AU (1) | AU2006342053A1 (enExample) |
| BR (1) | BRPI0620755A2 (enExample) |
| CA (1) | CA2635269A1 (enExample) |
| MX (1) | MX2008008453A (enExample) |
| RU (1) | RU2008130893A (enExample) |
| WO (1) | WO2007120362A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7507418B2 (en) * | 2005-09-09 | 2009-03-24 | Obetech, Llc | Adenovirus status as a predictor of body composition change, disease status, and treatment outcomes |
| KR20080114683A (ko) * | 2005-12-27 | 2008-12-31 | 오베테크, 엘엘씨 | 질병에 대한 바이오마커로서의 지방생성 아데노바이러스 |
| US20120082659A1 (en) * | 2007-10-02 | 2012-04-05 | Hartmut Land | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations |
| JP2009156254A (ja) * | 2007-12-05 | 2009-07-16 | Ibiden Co Ltd | 排気ガス処理体の保持シール部材及び排気ガス処理装置 |
| PT2268618E (pt) | 2008-03-03 | 2015-10-12 | Novartis Ag | Compostos e composições moduladores da actividade tlr |
| WO2010011440A2 (en) * | 2008-06-16 | 2010-01-28 | Obetech Llc | Diagnosis and treatment of lipogenic adenovirus infection associated with adipose tissue hypertrophy |
| AU2010258677B2 (en) | 2009-06-10 | 2016-10-06 | Glaxosmithkline Biologicals S.A. | Benzonaphthyridine-containing vaccines |
| TWI445708B (zh) | 2009-09-02 | 2014-07-21 | Irm Llc | 作為ｔｌｒ活性調節劑之化合物及組合物 |
| JP5988492B2 (ja) | 2009-09-02 | 2016-09-07 | ノバルティス アーゲー | Ｔｌｒ活性モジュレーターを含む免疫原性組成物 |
| WO2011050299A2 (en) * | 2009-10-22 | 2011-04-28 | Obetech Llc | Adenovirus infection in animals |
| WO2011057148A1 (en) | 2009-11-05 | 2011-05-12 | Irm Llc | Compounds and compositions as tlr-7 activity modulators |
| WO2011063131A1 (en) | 2009-11-18 | 2011-05-26 | Nohands, Llc | Method and system for preventing virus-related obesity and obesity related diseases |
| WO2011084549A1 (en) | 2009-12-15 | 2011-07-14 | Novartis Ag | Homogeneous suspension of immunopotentiating compounds and uses thereof |
| EA031379B1 (ru) | 2010-03-23 | 2018-12-28 | Новартис Аг | Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний |
| US20130052635A1 (en) * | 2010-03-25 | 2013-02-28 | Richard L. Atkinson | Method For Detecting Lipogenic Adenovirus |
| US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| JP5965397B2 (ja) * | 2010-07-08 | 2016-08-03 | ボード オブ スーパーバイザーズ オブ ルイジアナ ステート ユニバーシティー アンド アグリカルチュラル アンド メカニカル カレッジ | 非アルコール性脂肪肝疾患の予防および治療のためのアデノウイルスａｄ３６ｅ４ｏｒｆ１タンパク質 |
| US20130178517A1 (en) * | 2010-07-09 | 2013-07-11 | Richard L. Atkinson | Methods And Compositions For Treatment Of Lipogenic Virus Related Conditions |
| EP2651439B1 (en) | 2010-12-17 | 2018-09-19 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
| ES2670863T3 (es) | 2013-02-01 | 2018-06-01 | Glaxosmithkline Biologicals Sa | Administración intradérmica de composiciones inmunológicas que comprenden agonistas del receptor de tipo Toll |
| US9925254B2 (en) | 2014-11-05 | 2018-03-27 | The United States Of America As Represented By The Secretary Of The Navy | Synthetic antigen constructs against Campylobacter jejuni |
| US11458151B2 (en) | 2018-02-12 | 2022-10-04 | Inimmune Corporation | Toll-like receptor ligands |
| US20230333111A1 (en) * | 2018-10-05 | 2023-10-19 | Minomic International Ltd. | Biomarker combinations for determining aggressive prostate cancer |
| JP2023547677A (ja) | 2020-11-04 | 2023-11-13 | エリゴ・バイオサイエンス | キューティバクテリウム・アクネス組換えファージ、その産生方法及び使用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69435075T2 (de) * | 1993-03-17 | 2009-02-19 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten |
| WO1998044946A1 (en) * | 1997-04-04 | 1998-10-15 | Obetech, Llc | Viral obesity methods and compositions |
| JP2000072800A (ja) * | 1998-08-26 | 2000-03-07 | Toagosei Co Ltd | 抗アデノウイルス３７型モノクローナル抗体及びその用途 |
| CA2632013C (en) * | 2005-11-30 | 2013-02-26 | Wayne State University | Adenovirus 36 e4 orf 1 gene and protein and their uses |
| KR20080114683A (ko) * | 2005-12-27 | 2008-12-31 | 오베테크, 엘엘씨 | 질병에 대한 바이오마커로서의 지방생성 아데노바이러스 |
-
2006
- 2006-12-27 KR KR1020087018439A patent/KR20080114683A/ko not_active Ceased
- 2006-12-27 BR BRPI0620755-3A patent/BRPI0620755A2/pt not_active Application Discontinuation
- 2006-12-27 EP EP11176754A patent/EP2390372A1/en not_active Withdrawn
- 2006-12-27 JP JP2008548837A patent/JP2009521707A/ja active Pending
- 2006-12-27 RU RU2008130893/13A patent/RU2008130893A/ru not_active Application Discontinuation
- 2006-12-27 CN CN200680053371.XA patent/CN101389768B/zh not_active Expired - Fee Related
- 2006-12-27 MX MX2008008453A patent/MX2008008453A/es active IP Right Grant
- 2006-12-27 WO PCT/US2006/062632 patent/WO2007120362A2/en not_active Ceased
- 2006-12-27 US US11/616,799 patent/US7442511B2/en not_active Expired - Fee Related
- 2006-12-27 AU AU2006342053A patent/AU2006342053A1/en not_active Abandoned
- 2006-12-27 CA CA002635269A patent/CA2635269A1/en not_active Abandoned
- 2006-12-27 EP EP06851054.4A patent/EP1977009B1/en active Active
-
2008
- 2008-10-24 US US12/257,937 patent/US7745110B2/en not_active Expired - Fee Related
- 2008-10-24 US US12/257,967 patent/US7910310B2/en not_active Expired - Fee Related
-
2011
- 2011-02-07 US US13/022,219 patent/US20110189235A1/en not_active Abandoned
-
2013
- 2013-08-14 US US13/966,631 patent/US20130323273A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1977009A2 (en) | 2008-10-08 |
| US20090087833A1 (en) | 2009-04-02 |
| US20070218081A1 (en) | 2007-09-20 |
| US7910310B2 (en) | 2011-03-22 |
| CA2635269A1 (en) | 2007-10-25 |
| EP2390372A1 (en) | 2011-11-30 |
| US20130323273A1 (en) | 2013-12-05 |
| CN101389768B (zh) | 2015-11-25 |
| CN101389768A (zh) | 2009-03-18 |
| MX2008008453A (es) | 2008-11-28 |
| EP1977009B1 (en) | 2016-08-17 |
| US7442511B2 (en) | 2008-10-28 |
| KR20080114683A (ko) | 2008-12-31 |
| US7745110B2 (en) | 2010-06-29 |
| BRPI0620755A2 (pt) | 2011-11-22 |
| WO2007120362A2 (en) | 2007-10-25 |
| AU2006342053A1 (en) | 2007-10-25 |
| WO2007120362A3 (en) | 2008-08-14 |
| US20090087455A1 (en) | 2009-04-02 |
| US20110189235A1 (en) | 2011-08-04 |
| EP1977009A4 (en) | 2009-06-03 |
| JP2009521707A (ja) | 2009-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008130893A (ru) | Адипогенные аденовирусы как биомаркеры заболеваний | |
| Devaux et al. | ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome | |
| TWI333958B (enExample) | ||
| Filmus et al. | Glypican‐3: a marker and a therapeutic target in hepatocellular carcinoma | |
| DE69922261D1 (de) | Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten | |
| CN109765378B (zh) | 一种新的肝硬化或肝纤维化标志物 | |
| USRE42129E1 (en) | Viral obesity methods and compositions | |
| ATE419516T1 (de) | Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc) | |
| EA009861B1 (ru) | Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro | |
| ES2337791T3 (es) | Diagnostico y monitorizacion del carcinoma hepatocelular. | |
| EP3364987A1 (en) | Prognosis and treatment of squamous cell carcinomas | |
| JP7522918B2 (ja) | 抗ｈｍｍｗ抗体、それを含む組成物、及びそれをコードする核酸分子、並びにその使用 | |
| JP2022505327A (ja) | Ｓｙｔ１１抑制剤を有効成分として含む胃癌治療用組成物 | |
| CN1849136A (zh) | 癌症疾病改善抗体 | |
| CN109517898B (zh) | 一种食管癌检测、诊断或者预后评价制剂，治疗食管癌的药物及rnd2基因的应用 | |
| CN113395976A (zh) | 良性肿瘤的预防或治疗药 | |
| CN102257138B (zh) | 肿瘤抗原肽及其用途 | |
| JP2001522599A (ja) | 診断用及びワクチン用、ｃ型肝炎ウイルスエンベロープタンパク質由来マルチマーペプチド | |
| JP2003522774A (ja) | 異種型抗体療法の効力の診断のための方法 | |
| WO2011030300A1 (en) | Synthetic peptides from the sv40 t-antigen for use in an indirect elisa test for the identification of antibodies against simian virus 40 in human serum and other fluids | |
| CN111139299A (zh) | Josd2蛋白在制备治疗恶性肿瘤药物中的应用 | |
| WO2010050181A1 (ja) | Ｃ型肝炎ウイルスによる肝癌の発症および再発予防ワクチン | |
| WO2018156645A1 (en) | Preventative cancer therapy | |
| Naz et al. | 12. Diagnostic biomarkers in hepatocellular carcinoma | |
| JP3524537B2 (ja) | 癌の診断、モニタリング、ステージング、イメージングおよび処置のための新規方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20110117 |